All In Biotech

Free tool

FAERS Monitor: Clinolipid 20%

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 204508 or its brand name (Clinolipid 20%, Olive Oil, Soybean Oil). Reports on generic versions are filed under their own applications.

Reports

32

Serious

15

47% of reports

Hospitalization

5

Death reported

5

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • liver function test increased5
  • flushing4
  • nausea4
  • blood alkaline phosphatase increased3
  • drug ineffective3
  • pruritus3
  • urticaria3
  • alanine aminotransferase increased2
  • aspartate aminotransferase increased2
  • back pain2
  • blood triglycerides increased2
  • death2
  • dyspnoea2
  • jaundice2
  • product label confusion2

Reports by year received

View as table
YearReports
20144
20161
20191
20202
20214
20227
20232
20242
20255
20264

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,127 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product label confusion2225.659.0251
liver function test increasedSignal5153.168.4612
blood alkaline phosphatase increasedSignal379.527.1161
blood triglycerides increased274.419.481
jaundice248.912.852
flushingSignal425.910.373
aspartate aminotransferase increased224.86.525
alanine aminotransferase increased221.45.621
urticariaSignal311.84.020
back pain25.71.54
pruritusSignal35.11.76
nauseaSignal43.31.35
dyspnoea22.30.60
death21.50.40
drug ineffective31.50.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.